Would you like to edit some genes?
Taysha Gene Therapies initiated with a Buy at Canaccord 07:32 TSHA Canaccord analyst Whitney Ijem initiated coverage of Taysha Gene Therapies with a Buy rating and $16 price target. Ijem contends that there are "many recent gene therapy IPOs that are trading at a significant discount," but not many like Taysha that have a pivotal stage lead program with "a robust and long term data set," a second pipeline program with significant 2023 catalysts and a multi-billion dollar opportunity and an "interesting recent transaction" with a large pharma company that has "demonstrated interest in building out its gene therapy pipeline."
IDEA # 2-> TSHA
Taysha Gene Therapies initiated with a Buy at Canaccord 07:32 TSHA Canaccord analyst Whitney Ijem initiated coverage of Taysha Gene Therapies with a Buy rating and $16 price target. Ijem contends that there are "many recent gene therapy IPOs that are trading at a significant discount," but not many like Taysha that have a pivotal stage lead program with "a robust and long term data set," a second pipeline program with significant 2023 catalysts and a multi-billion dollar opportunity and an "interesting recent transaction" with a large pharma company that has "demonstrated interest in building out its gene therapy pipeline."
IDEA # 2-> TSHA
